Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ogy platform for therapeutic antibody fragments, we started preclinical development of ESBA105 in mid 2006. Now to move this swiftly into the clinic is a truly exciting time for the company. ESBA105 represents a new generation of antibody fragment therapeutics that have favourable biochemical properties over earlier classes of antibody fragments, such as high stability, solubility and high monomeric content. This allows us to deliver the drug topically, without any need to stabilize or modify the protein. Thanks to the small protein size as compared to conventional antibodies, ESBA105 efficiently penetrates into all segments of the eye, which results in a high local concentration where the drug is needed to inhibit inflammation. As this is associated with low systemic drug exposure, this novel therapeutic approach has a very low risk of provoking systemic adverse effects."

ESBATech is the first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragments frameworks. The company is advancing a pipeline of novel, antibody fragment therapeutics for topical and/or local delivery, to ensure safe and convenient patient therapy.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. Current venture investors include SV Life Sciences,
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Stryker Orthopaedics, the ... Champions Tour, is rounding out its debut year of ... Scottsdale, AZ. This marks the ... Champions Tour that the brand has activated on-site with ... educate golf fans on the importance of joint health.  ...
(Date:10/30/2014)... Oct. 30, 2014  Electronic health records uptake ... result of government initiatives and the considerable resources ... have invested over the past five years. Electronic ... IT, and U.S. clinicians use them on a ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & Sullivan,s ...
(Date:10/30/2014)... , Oct. 30, 2014 Molecular Profiles Ltd., ... CBRX ) and Maryland -based Xceleron ... improved efficiency during clinical development that will be launched ... next week. This partnership extends Molecular Profiles, ... it launched earlier this month. The company also has ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... 2012 Sorbent Therapeutics, Inc. a biopharmaceutical company developing ... from its Phase 2a clinical study of CLP1001.  In ... kidney disease, CLP1001 demonstrated improvement in heart failure symptoms ... the randomized, double-blind Phase 2a study were presented in ...
...  Eli Lilly and Company (NYSE: LLY ) ... 1 (GLP-1) analog being studied as a once-weekly treatment ... non-inferiority for mean 24-hour systolic blood pressure (SBP, or ... results came from a Phase II study that compared ...
Cached Medicine Technology:Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 2Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 3Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 2Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 3Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 4
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 REV'D Provision ... are now available through a unique service called, ... designed to empower the everyday athlete. The Feed has ... athletes and created a system to pass that information ... see REV’D® is now available on The Feed!” says ...
(Date:10/30/2014)... Victory Healthcare, a privately owned ... quarter infection rates and patient satisfaction scores. The ... only two percent or less, and the medical ... percent. , “We are delighted with our strong ... scores,” said Robert Helms, chairman and CEO of ...
(Date:10/30/2014)... (HealthDay News) -- Scientists who used stem cells to ... breakthrough could provide a new way to learn more ... The team used human pluripotent stem cells -- which ... -- to grow the functional miniature stomachs, to study ... cause of ulcers and stomach cancer. The miniature ...
(Date:10/30/2014)... (HealthDay News) -- Many U.S. colleges have indoor ... tanning increases the risk for skin cancer, researchers ... particularly white women, so colleges should adopt tanning-free ... said. "Public health efforts are needed to ... the harms that indoor tanning poses to young ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2
... risk of hypertension, hardening of arteries , , FRIDAY, May 15 ... harbor could be a cause of high blood pressure, animal ... likely to develop not only high blood pressure but also ... report in the May 15 issue of PLoS Pathogens ...
... Boston Scientific Corporation (NYSE: BSX ) ... news announcements at the annual EuroPCR Scientific Program, which ... are pleased to be announcing additional analyses from the ... outcomes, as well as insights on the design and ...
... ATLANTA, May 15 Paul Capital Healthcare today announced ... a panel on non-traditional forms of financing at the ... with how to evaluate non-dilutive financing options that can ... development, the panel, "Non-dilutive and Other Non-traditional Forms of ...
... establish Group B Strep colonization of pregnant women and ... newbornsGBS PNA FISH shown to detect up to 42% ... and VEDBAEK, Denmark, May 15 AdvanDx today announced ... for detection of Streptococcus agalactiae , aka Group ...
... May 15 Endocare, Inc. (Nasdaq: ENDO ... development of minimally invasive technologies used by urologists and ... results for the first quarter ended March 31, 2009. ... increase in revenue and strong margins.Total revenues for the ...
... 400umol/g delivers Market Leading Economies to Reduce Synthesis Costs and ... ... (PRWEB) May 15, 2009 -- Kinovate Life Sciences, Inc, the ... announcing the successful development of its next generation high loading ...
Cached Medicine News:Health News:Viral Infection Might Trigger High Blood Pressure 2Health News:Viral Infection Might Trigger High Blood Pressure 3Health News:Boston Scientific Announces Schedule for EuroPCR 2009 2Health News:Boston Scientific Announces Schedule for EuroPCR 2009 3Health News:Boston Scientific Announces Schedule for EuroPCR 2009 4Health News:Boston Scientific Announces Schedule for EuroPCR 2009 5Health News:Boston Scientific Announces Schedule for EuroPCR 2009 6Health News:Paul Capital Healthcare to Participate in Panel on Non-Traditional Forms of Financing 2Health News:AdvanDx Receives FDA 510(k) Clearance for GBS PNA FISH(R) for Rapid Detection of Group B Strep from Lim Broths 2Health News:AdvanDx Receives FDA 510(k) Clearance for GBS PNA FISH(R) for Rapid Detection of Group B Strep from Lim Broths 3Health News:Endocare Reports 2009 First Quarter Financial Results 2Health News:Endocare Reports 2009 First Quarter Financial Results 3Health News:Endocare Reports 2009 First Quarter Financial Results 4Health News:Endocare Reports 2009 First Quarter Financial Results 5Health News:Endocare Reports 2009 First Quarter Financial Results 6Health News:Endocare Reports 2009 First Quarter Financial Results 7Health News:Endocare Reports 2009 First Quarter Financial Results 8Health News:Endocare Reports 2009 First Quarter Financial Results 9Health News:Endocare Reports 2009 First Quarter Financial Results 10Health News:Endocare Reports 2009 First Quarter Financial Results 11Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 2Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 3Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 4
... Excellent performance, small footprint, simple intuitive programming ... Primus 25 the ideal personal cycler in ... flexiblock design and the self-adjusting heated lid ... 13x 0.5ml vessels or a microplate of ...
... 96 temperature cyclers, the gradient block can be ... up to 14 or 22 across the 40- ... of up to 2C between adjacent wells in ... to 12 different annealing temperatures in a single ...
... instrument and custom filter wheels with ... The standard filter set includes: FAM/SYBR ... Red (585nm-610nm), Cy5 (635nm-665nm) and Cy3 ... analysis software, Beacon Designer oligo software, ...
... a rapid, real-time thermal cycler used for ... automating much of the testing process, and ... is the fastest, easiest to use, and ... The SmartCycler delivers highly accurate and consistent ...
Medicine Products: